This article was originally published on MedTech Intelligence. With patients and medical providers across Asia and around the world forced by the global pandemic to rely on online platforms more than ever before, the medical device industry is finding itself uniquely vulnerable... Read More
Qualified research institutions that develop their own pharmaceuticals will be eligible to hold marketing authorization permits in China under new legal guidance that went into effect in late September. Since 2015, when China first began implementing its Marketing Authorization Holder (MAH) system,... Read More
Sales of diagnostic mammography equipment in the Asia-Pacific region is expected to rise significantly over the next eight years, according to two recently published studies. The reports by Globalcan and GlobalData vary in their specific findings. But both project compound annual growth... Read More
Radio Frequency Identification (RFID), a fast-developing technology that uses radio waves to collect and transfer data, is increasingly being adopted in healthcare markets across the Asia Pacific region and around the globe. A study by Precedence Research found sales of the technology,... Read More
A centralized procurement system launched by the Chinese government will make critically needed coronary stents available directly to Chinese consumers for a fraction of their current price, officials announced in November. The average price of coronary stents for patients in China is... Read More
In response to growing concern that pharmaceuticals imported to China do not always adhere to the same safety guidelines they follow when marketed abroad, Chinese health authorities in October put forward a proposal to update domestic regulations governing drug recalls. The proposed... Read More
Moving to better its system for settling patent disputes while also providing generic drugs a market pathway, Chinese authorities in September issued a draft policy addressing the relationship between market approval of generic drugs and the patent status of branded equivalents. The... Read More
Accelerating efforts to make the island of Hainan into a center for medical innovation—and medical tourism — local authorities have approved an insurance plan for the island that will cover foreign drugs and treatments not yet approved on the mainland. The government-backed... Read More
Western investors are increasingly investing in Chinese biotechnology firms, driven by a surge in demand for cutting edge treatments for the novel coronavirus and other new therapies being developed in China. Over the past five years, Chinese firms have moved away from... Read More
China’s Center for Drug Evaluation has clarified its requirements for how pharmaceuticals manufactured outside its borders are tested in clinical trials. Under the new requirements, China’s Center for Drug Evaluation (CDE) will continue to permit the importing of drugs successfully evaluated in... Read More